Jaguar Health earnings release, May 20, 2026
Jaguar Health Reports First Quarter 2026 Financials
Net revenue increased 816% in Q1 2026 vs. Q1 2025, and increased 527% in Q1 2026 vs. Q4 2025, buoyed by license of U.S. commercial rights for Mytesi® and Canalevia®
-CA1
Company continues its focus on crofelemer development efforts for rare-disease intestinal failure indications; two crofelemer presentations in pediatric intestinal failure patients with microvillus inclusion disease (MVID) and short bowel syndrome
(SBS-IF) to be made at⁵⁸ th
Annual European
Society for
Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN) Meeting in June 2026
REMINDERS:
Jaguar to host investor webcast Tuesday, May 26 at 8:30 a.m. Eastern regarding Q1 2026 financials and company updates (click here to register); Jaguar CEO Lisa Conte to present virtually on Thursday, May 28 at 10 a.m. Eastern at Lytham Partners Spring 2026 Investor Conference (click here to register)
SAN FRANCISCO, CA / May 20, 2026 /
Jaguar Health, Inc. (
NASDAQ: JAGX)
(“Jaguar” or the “Company”) today reported its consolidated first-quarter 2026 financial results.
2026 FIRST QUARTER COMPANY
FINANCIAL RESULTS:
Note Regarding Use of
Non-GAAP
Measures
The Company supplements its condensed consolidated financial statements presented on a GAAP basis by providing non-GAAP
EBITDA and non-GAAP recurring EBITDA, which are considered non-GAAP under applicable SEC rules. Jaguar believes that the disclosure items of these non-GAAP measures provide investors with additional information that reflects the basis upon which Company management assesses and operates the business. These non-GAAP financial measures are not in accordance with GAAP and should not be viewed in isolation or as substitutes for GAAP net sales and GAAP net loss and are not substitutes for, or superior to, measures of financial performance in conformity with GAAP.
The Company defines non-GAAP
EBITDA as net loss before interest expense and other expense, depreciation of property and equipment, amortization of intangible assets, share-based compensation expense and provision for or benefit from income taxes. The Company defines non-GAAP
Recurring EBITDA as non-GAAP
EBITDA adjusted for certain non-recurring revenues and expenses. Company management believes that non-GAAP
EBITDA and non-GAAP
Recurring EBITDA are meaningful indicators of Jaguar’s performance and provide useful information to investors regarding the Company’s results of operations and financial condition.
About Crofelemer
Crofelemer is the only oral
FDA-approved prescription drug under botanical guidance. It is plant-based, extracted and purified from the red bark sap of the
Croton lechleri tree in the Amazon Rainforest. Napo Pharmaceuticals, a Jaguar family company, has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for Indigenous communities.
About the Jaguar Health Family of Companies
Jaguar
Health, Inc. (“Jaguar”) develops novel proprietary prescription drugs sustainably derived from plants for people with complicated gastrointestinal (“GI”) disease states. Jaguar family companies Napo Pharmaceuticals, Inc. and
Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including microvillus inclusion disease and short bowel syndrome. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar’s Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo
Pharmaceuticals, visit napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
About Mytesi®
Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
See full Prescribing Information at
Mytesi.com. Crofelemer, the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal
Croton lechleri tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.
About Gelclair®
INDICATIONS
GELCLAIR® has a mechanical action indicated for the management of pain and relief of pain by adhering to the mucosal surface of the mouth, soothing oral lesions of various etiologies, including oral mucositis/stomatitis (may be caused by chemotherapy or radiation therapy), irritation due to oral surgery, traumatic ulcers caused by braces or ill-fitting dentures, or disease. Also, indicated for diffuse aphthous ulcers.
IMPORTANT SAFETY INFORMATION
You are encouraged to report negative side effects of prescription medical products to the FDA. Visit www.fda.gov/safety/medwatch or call
1-855-273-0468.
Please see full
Prescribing Information at:... (truncated)ibing-information-instructions-for-use.pdf
Important Safety Information About Canalevia®
-CA1
For oral use in dogs only. Not for use in humans. Keep
Canalevia-CA1
(crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using
Canalevia-CA1, rule out infectious etiologies of diarrhea.
Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.
Caution:
Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed.
It is a violation of Federal law to use this product other than as directed in the labeling.
Conditionally approved by FDA pending a full demonstration of effectiveness under application number
141-552.
See full Prescribing
Information at
Canalevia.com.
Financial statements
Income Statement
Financial Highlights — 2026 FIRST QUARTER COMPANY FINANCIAL RESULTS: (in thousands, except per share amounts)
| Three Months Ending March 31, – 2026 | Three Months Ending March 31, – 2025 | $ change | % change | |
|---|---|---|---|---|
| License and grant revenue, net | 19,068 | 43 | 19,025 | 44244.0% |
| Product revenue, net | 1,204 | 2,171 | -967 | -45.0% |
| Total revenue, net | 20,272 | 2,214 | 18,058 | 816.0% |
| Income (loss) from operations | 10,182 | -9,421 | 19,602 | 208.0% |
| Net loss attributable to common stockholders | -7,015 | -10,464 | 3,449 | 33.0% |
| Net loss per share, basic and diluted | -13.6 | -584.45 | 571 | 98.0% |
Income Statement
Three Months Ending — 2026 FIRST QUARTER COMPANY FINANCIAL RESULTS: (in thousands)
| Three Months Ending – March 31, – 2026 – (unaudited) | Three Months Ending – March 31, – 2025 – (unaudited) | $ change | % change | ||
|---|---|---|---|---|---|
| Net loss attributable to common stockholders | -7,015 | -10,464 | 3,449 | 33.0% | |
| Adjustments: | Interest expense | 699 | -56 | 755 | 1349.0% |
| Adjustments: | Property and equipment depreciation | 10 | 17 | -7 | -40.0% |
| Adjustments: | Amortization of intangible assets | 463 | 463 | 0 | 0.0% |
| Adjustments: | Share-based compensation expense | 155 | 301 | -146 | -48.0% |
| Adjustments: | Non-GAAP EBITDA | -5,688 | -9,739 | 4,051 | -42.0% |
| Adjustments: | Loss on extinguishment of debt | 628 | 628 | 100.0% | |
| Adjustments: | Non-GAAP Recurring EBITDA | -5,060 | -9,739 | 4,679 | 48.0% |
Full release
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements.” These include statements regarding Jaguar’s expectation that it will hold an investor webcast on May 26, 2026, and Jaguar’s expectation that Jaguar management will present at the Lytham Partners Spring 2026 Investor Conference. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,”
“contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Source:
Jaguar Health, Inc.
Contact: hello@jaguar.health
Jaguar-JAGX